Enter Wall Street with Street Insider Premium. Claim your 1-week free trial here.
BERKELEY, Calif., September 29, 2021 (GLOBE NEWSWIRE) – Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced it has appointed Ran Zheng to its directors board. Ms. Zheng brings more than 25 years of experience leading the biotechnology industry in the development of biologics with extensive expertise in the technical operations and manufacturing of gene and cell therapy.
“I am pleased to welcome Ran to our Board of Directors,” said Rachel Haurwitz, Ph.D., President and CEO of Caribou. “Ran brings a wealth of strategic and operational expertise in the development of gene and cell therapies, from engineering and process development to manufacturing and supply chain management. We look forward to benefiting from his perspective and experience as we advance our allogeneic CAR-T and CAR-NK chDNA-modified cell therapies for the potential treatment of hematologic malignancies and difficult solid tumors. “
“Caribou has developed an innovative and differentiated genome editing technology that enables a pipeline of ready-to-use allogeneic cell therapies designed to increase persistence and anti-tumor activity,” said Ms. Zheng. “Caribou’s work to develop allogeneic cell therapies has the potential to make a real difference in the lives of critically ill patients. Caribou is clearly a leader in this field and I am delighted to join its board of directors.
Ms. Zheng is currently President and CEO and a member of the Board of Directors of Landmark Bio, a public interest limited liability company formed to advance the development of new transformative drugs by translating today’s cutting edge research into revolutionary therapies of tomorrow. Landmark Bio focuses on emerging technologies of cell and gene therapy, mRNA and other new modalities to enable and accelerate drug development and biomedical innovation. Prior to joining Landmark Bio earlier this year, Ms. Zheng most recently served as Technical Director at Orchard Therapeutics, a global commercial-stage gene therapy company specializing in gene therapies based on hematopoietic stem cells. In this role, Ms. Zheng led the technical operations organization and helped advance the company’s product portfolio, including contributing to the approval of Libmeldy® therapy in Europe, the leading gene therapy product for metachromatic leukodystrophy. Ms. Zheng has also held senior positions at several biotech companies, including Genzyme (now Sanofi) and Amgen. At Amgen, Ms. Zheng has held positions of increasing responsibility in process development, clinical and commercial manufacturing, as well as the supply chain, and has been instrumental in building differentiated manufacturing capabilities for supply. clinical and commercial product launch to accelerate the clinic and accelerate time-to-market strategies for Amgen’s innovative products. Ms. Zheng holds a master’s degree in microbial engineering from the University of Minnesota and a bachelor’s degree in biology from Peking Forestry University.
About Caribou’s New Next-Generation CRISPR PlatformCRISPR genome editing uses easy-to-design modular biological tools to modify the DNA of living cells. CRISPR type II systems have two basic components: the nuclease protein which cuts DNA and the RNA molecule (s) which guide the nuclease to generate a site-specific double-stranded break, leading to a change at the site. targeted genomics. CRISPR systems occasionally alter unintentional genomic sites, known as off-target editing, which can result in harmful effects on cell function and phenotype. In response to this challenge, Caribou has developed chRDNAs (pronounced “chardonnays”), hybrid RNA-DNA guides that drive much more precise genome editing than all-RNA guides. Caribou is deploying the power of chRDNA technology to perform high-efficiency multiple modifications, including multiplex gene insertions, to develop CRISPR-modified therapies.
About Caribou Biosciences, Inc.Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying the company’s proprietary chRDNA technology to the development of next-generation, genome-modified cell therapies. The company is developing a pipeline of ready-to-use, genome-edited CAR-T and CAR-NK cell therapies for the treatment of hematologic malignancies and solid tumors against cell surface targets for which CAR-T autologous cell therapies have already been demonstrated. clinical proof of concept, as well as additional emerging targets.
Forward-looking statementsThis press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements relating to Caribou’s cell therapy pipeline, potential treatments and expectations regarding his activities. Management believes these forward-looking statements are reasonable as they are made. However, these forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include, but are not limited to, risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of current and future research and development programs, preclinical trials and clinical, as well as other risk factors described over time. from time to time in documents filed by Caribou with the Securities and Exchange Commission, including its final prospectus filed on July 23, 2021. In light of the material uncertainties in these forward-looking statements, you should not rely on forward-looking statements such as predictions of future events. Except as required by law, Caribou assumes no obligation to publicly update forward-looking statements for any reason.
For more information on Caribou, visit www.cariboubio.com and follow the company @CaribouBio.
“Caribou Biosciences” and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.
Source: Caribou Biosciences, Inc.